碳青霉烯耐药革兰阴性杆菌的耐药机制及抗菌药物的研究进展
Research Progress on Drug Resistance Mechanism and Antibacterial Drugs of Carbapenem-resistant Gram-negative Bacilli
刘洁 1赵建平2
作者信息
- 1. 内蒙古医科大学内蒙古临床医学院,呼和浩特 010050
- 2. 内蒙古自治区人民医院检验科,呼和浩特 010010
- 折叠
摘要
碳青霉烯类抗生素是一类非典型的β-内酰胺类药物,是目前抗菌谱最广、杀菌活性最强的抗生素,然而随着此类抗生素的广泛使用,碳青霉烯耐药革兰阴性杆菌(Carbapenem-resistant organism,CRO)在全球范围内扩散,导致临床选择抗菌药物越来越艰难,给临床治疗带来了新的挑战.本文从碳青霉烯酶的产生、通道蛋白的缺失、外排泵的过度表达、药物结合位点的改变、生物膜的形成等5个方面介绍了碳青霉烯类抗生素的耐药机制,以及对抗菌药物的选择进行综述,为临床预防和治疗CRO提供科学依据.
Abstract
A class of atypical β-lactam antibiotics with the strongest bactericidal activity and the largest antibacterial spectrum are the carbapenem antibiotics.However,with the widespread use of such antibiotics,Carbapenem-resistant Organisms(CRO)have spread around the world,posing new challenges to the selection of clinical antibiotics.The synthesis of carbapenemase(the most significant),the loss of channel protein,the overexpression of efflux pump,the modification of drug binding sites,and the formation of biofilm are the five features from which the resistance mechanism of carbapenem antibiotics was introduced in this study.In addition,the selection of antibiotics was reviewed to provide a scientific basis for clinical prevention and treatment of CRO
关键词
碳青霉烯类抗生素/革兰阴性杆菌/耐药机制/治疗药物/耐药性/联合用药Key words
carbapenem antibiotics/gram-negative bacilli/drug resistance mechanism/antibacterial drugs/tolerance/drug combination引用本文复制引用
基金项目
内蒙古自治区自然科学基金项目(2017MS08144)
内蒙古自治区科技计划项目(201702113)
出版年
2024
NETL
NSTL
万方数据